Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting Report

The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.

Sara Harsini, Heather Saprunoff, Behnoud Mohammadi, Tina Alden, Don Wilson and Francois Benard
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1281;
Sara Harsini
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Saprunoff
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Behnoud Mohammadi
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tina Alden
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don Wilson
2University of British Columbia Vancouver BC Canada
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Benard
2University of British Columbia Vancouver BC Canada
1BC Cancer Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

1281

Objectives: The prostate-specific membrane antigen (PSMA) is an excellent target for theranostic applications in prostate cancer. However, PSMA-targeted radioligand therapy can cause undesirable effects due to high accumulation of PSMA radiotracers in salivary glands and kidneys. This prospective study assessed orally administered monosodium glutamate (MSG) as a potential means of reducing kidney and salivary gland radiation exposure using a PSMA targeting radiotracer.

Methods: Ten patients with prostate cancer and biochemical recurrence post radical prostatectomy/curative intent radiotherapy were enrolled. The study was performed using a double-blind, placebo-controlled method, where each subject served as his own control. Two 18F-DCFPyl PET/CT imaging sessions were performed 3 - 7 days apart, following oral administration of either 12.7 g of MSG or placebo, 30 minutes prior to radiotracer injection. Data from the two sets of images were analyzed by placing regions of interest on lacrimal, parotid and submandibular glands, left ventricle blood pool, liver, spleen, kidneys, colon, urinary bladder, gluteus muscle and malignant lesions. The results from MSG and placebo scans were compared by paired analysis of the ROI data. Vital signs were measured and adverse events recorded for both scans.

Results: A total of 142 pathological lesions along with normal tissues were analyzed in 10 patients on both control and MSG 18F-DCFPyL PET/CT images. As hypothesized a priori, there was a significant decrease in maximal standardized uptake values (SULmax) corrected for lean body mass on images obtained following MSG administration in the parotids (24 ± 14%, P value=0.001), submandibular glands (35 ± 11%, P<0.001) and kidneys (23 ± 26%, P=0.014). On post-hoc analysis, significant decreases were also observed in lacrimal glands (49 ± 13%, P<0.001), liver (15 ± 6%, P<0.001), spleen (28 ± 13%, P=0.001) and colon (44 ± 13%, P<0.001). Mildly lower blood pool mean standardized uptake value (SULmean) was observed after MSG administration (11 ± 13%, P=0.021). However, significantly lower radiotracer uptake in terms of SULmean, SULpeak, and SULmax was observed in malignant lesions on scans performed after MSG administration compared to the placebo studies (SULmax median decrease 33%, range -1 to 75%, P<0.001). No significant adverse events occurred and vital signs were stable following placebo or MSG administration.

Conclusions: Orally administered MSG significantly decreased salivary gland, kidney and other normal organ PSMA radiotracer uptake in human subjects, using 18F-DCFPyL as an exemplar. However, MSG also caused a corresponding reduction in tumor uptake, which may limit the benefits of this approach for diagnostic and therapeutic applications.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
Sara Harsini, Heather Saprunoff, Behnoud Mohammadi, Tina Alden, Don Wilson, Francois Benard
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1281;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
Sara Harsini, Heather Saprunoff, Behnoud Mohammadi, Tina Alden, Don Wilson, Francois Benard
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 1281;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Rest Dose Spillover Correction of Stress Blood Flow Measurements in Digital Rb-82 Myocardial Perfusion PET/CT Imaging
  • Radiolabeled hyaluronic acid (HA) fragments for lymphatic imaging
  • Reduction of injected activity for MBF with a CZT Cardiac SPECT Camera
Show more

GU - Radioligand Therapy (Poster Session)

  • Pretherapeutic SUV as a predictive parameter for therapy response in PSMA radioligand therapy - correlation of pre- and posttherapeutic SUV in 68Ga-PSMA-11 PET with absorbed dose and PSA-response
  • Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer
  • Efficacy and safety of 177Lu-PSMA radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study
Show more GU - Radioligand Therapy (Poster Session)

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire